VYNE Therapeutics Approves 1-for-50 Reverse Stock Split Ahead Of Merger With Yarrow Bioscience
VYNE Therapeutics said its board approved a 1-for-50 reverse stock split ahead of its merger with Yarrow Bioscience. VYNE shares would fall from about 33.4M to 0.7M. After the merger, trading is expected to start July 27, 2026 as Yarrow Bioscience (YARW). A $17.3M special cash dividend, about $0.40242 per share, is payable to holders of record July 22.
How this was made
The 30-second read
Why it matters
The board-approved reverse split and the special cash dividend tied to the merger agreement introduce near-term trading catalysts and entitlement-driven price behavior, while the expected merger close and new ticker start date set the next major event window.
Market read
Deal progression plus a large reverse split and a defined special dividend schedule create actionable event timing for traders managing corporate-action and merger-close risk.
What to watch
The due-bill period and entitlement rules can create short-term arbitrage flows and unusual volume, which may distort directional signals around the corporate-action dates.
Background
VYNE is a clinical-stage biopharma developing BET inhibitors via its InhiBET platform; Yarrow Bioscience is a clinical-stage autoimmune thyroid disease-focused company with lead candidate YB-101 in Phase 2.
Ticker impact
VYNE’s board approved a 1-for-50 reverse split tied to the anticipated merger closing, cutting shares from ~33.4M to ~0.7M.
Elevated volatility into the July 22 record date and July 24 ex-dividend/due-bill period, with potential post-merger re-rating.
The article discloses concrete corporate-action dates (record, ex-dividend, expected merger close) and a large share-count change, which typically affects price behavior even without new operating fundamentals.
Market effects
Biopharma M&A and clinical-stage deal execution risk may remain in focus, but the article is deal-mechanics specific rather than sector-wide.
Primarily US-listed microcap/small-cap trading dynamics due to the reverse split and ticker transition.
Limited, as the disclosure is company-specific and does not indicate broader cross-border market effects.
Counterpoint
The reverse split itself may be largely mechanical, so price action could be dominated by dividend entitlement and merger-close probability rather than any fundamental re-rating.
Key entities
- public_companyVYNE Therapeutics Inc.
Board approved a 1-for-50 reverse stock split in connection with the anticipated merger with Yarrow Bioscience.
- public_companyYarrow Bioscience, Inc.
Combined company expected to begin trading July 27 under the new name and ticker YARW.
- venueNasdaq
Advised July 24, 2026 as the ex-dividend date and due-bill entitlement timing.
